174 related articles for article (PubMed ID: 38344143)
1. IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells
Wang Y; Shimosaki S; Ikebe E; Iha H; Yamamoto JI; Fife N; Ichikawa T; Hori M; Ogata M; Tsukamoto Y; Hijiya N; Moriyama M; Hagiwara S; Kusano S; Saito M; Ahmed K; Nishizono A; Handa H; Morishita K
Front Oncol; 2023; 13():1272528. PubMed ID: 38344143
[TBL] [Abstract][Full Text] [Related]
2. Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.
Kondo N; Nagano Y; Hasegawa A; Ishizawa M; Katagiri K; Yoneda T; Masuda T; Kannagi M
Biochem Biophys Res Commun; 2021 Oct; 574():104-109. PubMed ID: 34455369
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.
Tanaka T; Inamoto Y; Ito A; Watanabe M; Takeda W; Aoki J; Kim SW; Fukuda T
Hematol Oncol; 2023 Aug; 41(3):389-395. PubMed ID: 36513602
[TBL] [Abstract][Full Text] [Related]
4. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
Sakamoto H; Itonaga H; Sawayama Y; Furumoto T; Fujioka M; Chiwata M; Toriyama E; Kasai S; Nakashima J; Horai M; Kato T; Sato S; Ando K; Taguchi J; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Miyazaki Y
Hematol Oncol; 2020 Apr; 38(2):162-170. PubMed ID: 31922287
[TBL] [Abstract][Full Text] [Related]
5. Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
Gooding S; Ansari-Pour N; Kazeroun M; Karagoz K; Polonskaia A; Salazar M; Fitzsimons E; Sirinukunwattana K; Chavda S; Ortiz Estevez M; Towfic F; Flynt E; Pierceall W; Royston D; Yong K; Ramasamy K; Vyas P; Thakurta A
Blood; 2022 Oct; 140(16):1816-1821. PubMed ID: 35853156
[TBL] [Abstract][Full Text] [Related]
6. [Progress in the management of ATL].
Ishitsuka K
Rinsho Ketsueki; 2017; 58(6):676-682. PubMed ID: 28680001
[TBL] [Abstract][Full Text] [Related]
7. Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract.
Tsubokura Y; Yoshimura H; Satake A; Nasa Y; Tsuji R; Ito T; Nomura S
Immun Inflamm Dis; 2022 Sep; 10(9):e688. PubMed ID: 36039651
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood Adv; 2019 Jul; 3(14):2105-2117. PubMed ID: 31300418
[TBL] [Abstract][Full Text] [Related]
9. Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth.
Sakamoto H; Ando K; Imaizumi Y; Mishima H; Kinoshita A; Kobayashi Y; Kitanosono H; Kato T; Sawayama Y; Sato S; Hata T; Nakashima M; Yoshiura KI; Miyazaki Y
Cancer Sci; 2022 Dec; 113(12):4092-4103. PubMed ID: 36047964
[TBL] [Abstract][Full Text] [Related]
10. Cell death induced by dorsomorphin in adult T-cell leukemia/lymphoma is AMPK-independent.
Aikawa A; Kozako T; Uchida Y; Yoshimitsu M; Ishitsuka K; Ohsugi T; Honda SI
FEBS J; 2020 Sep; 287(18):4005-4015. PubMed ID: 32027454
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Type I Interferon Production by Human T-Cell Leukemia Virus Type 1 Oncoprotein Tax through Inhibition of IRF3 Phosphorylation.
Yuen CK; Chan CP; Fung SY; Wang PH; Wong WM; Tang HV; Yuen KS; Chan CP; Jin DY; Kok KH
J Virol; 2016 Apr; 90(8):3902-3912. PubMed ID: 26819312
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract][Full Text] [Related]
13. [New treatment strategy for adult T-cell leukemia targeting for anti-tumor immunity and a longevity gene-encoded protein].
Kozako T
Yakugaku Zasshi; 2011; 131(7):1061-72. PubMed ID: 21720136
[TBL] [Abstract][Full Text] [Related]
14. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs.
Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.
Otáhal P; Průková D; Král V; Fabry M; Vočková P; Latečková L; Trněný M; Klener P
Oncoimmunology; 2016 Apr; 5(4):e1115940. PubMed ID: 27141398
[TBL] [Abstract][Full Text] [Related]
16. CDK9 Inhibitor Induces Apoptosis, Autophagy, and Suppression of Tumor Growth in Adult T-Cell Leukemia/Lymphoma.
Kato N; Kozako T; Ohsugi T; Uchida Y; Yoshimitsu M; Ishitsuka K; Aikawa A; Honda SI
Biol Pharm Bull; 2023; 46(9):1269-1276. PubMed ID: 37661406
[TBL] [Abstract][Full Text] [Related]
17. Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma.
Domenger A; Ricci D; Mayau V; Majlessi L; Marcireau C; Dadaglio G; Demangel C
Front Oncol; 2023; 13():1110916. PubMed ID: 36776330
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma.
Hirano M; Imai Y; Kaito Y; Murayama T; Sato K; Ishida T; Yamamoto J; Ito T; Futami M; Ri M; Yasui H; Denda T; Tanaka Y; Ota Y; Nojima M; Kamikubo Y; Gotoh N; Iida S; Handa H; Tojo A
J Exp Clin Cancer Res; 2021 Mar; 40(1):110. PubMed ID: 33757580
[TBL] [Abstract][Full Text] [Related]
19. Role of IRF4 in resistance to immunomodulatory (IMid) compounds
Bertrand E; Jouy N; Manier S; Fouquet G; Guidez S; Boyle E; Noel S; Tomowiak C; Herbaux C; Schraen S; Preudhomme C; Quesnel B; Poulain S; Leleu X
Oncotarget; 2017 Dec; 8(68):112917-112927. PubMed ID: 29348877
[TBL] [Abstract][Full Text] [Related]
20. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
